Drugs / A/Shanghai/02/2013 (H7N9) MIV
A/Shanghai/02/2013 (H7N9) MIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02206464 | Jul 2014 → Jan 2016 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/Shanghai/02/2013 (H7N9) MIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02206464 ↗ |
| Known as | A/Shanghai/2/2013(H7N9) MIV | “The inactivated H7N9 vaccine is monovalent subunit virion vaccine, A/Shanghai/2/2013(H7N9) MIV, manufactured by Sanofi Pasteur, Inc (Swiftwater, PA), and supplied at 30 mcg/0.5...” NCT02206464 ↗ |
| Known as | H7N9 MIV | “Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)” NCT02206464 ↗ |
| Modality | Vaccine | “The inactivated H7N9 vaccine is monovalent subunit virion vaccine” NCT02206464 ↗ |
| Route | Intramuscular | “The H7N9 MIV vaccinations will be 45 mcg administered as a 0.75 mL IM injection” NCT02206464 ↗ |